Ablexis licenses antibodies for CAR-T development

By Maggie Lynch contact

- Last updated on GMT


Related tags: CAR-T, Mouse models, transgenic, Oncology, Research, Antibody, preclinical, Preclinical contract research

The clinical-stage biotechnology company Allogene has licensed Ablexis’ antibodies for the use of CAR-T therapy research and development.

San Francisco, CA-based Allogene licensed Ablexis' antibodies and was granted the rights to research, develop, and commercialize certain AlivaMab antibodies against several targets.

The technology, according to Ablexis, and has been validated for antibody drug discovery by Ablexis and partners in various formats including regular antibodies, bispecifics, and CAR T cells.

Larry Green, CEO of Ablexis, said in a statement that this agreement can highlight the potential applications of AlivaMab antibodies in drug modalities such as CAR-T. Allogene is working towards the development of allogenic CAR-T therapies.

Green told us, “If using a transgenic mouse, then fully human, highly-potent, therapeutic-quality antibodies can be readily produced, which speeds the discovery phase and reduces risks in both pre-clinical and clinical development.”

Financial terms of the agreement were not disclosed.

Related news

Show more

Related products

show more

Paper vs ePRO Data Collection Methods

Paper vs ePRO Data Collection Methods

Signant Health | 19-Oct-2021 | Technical / White Paper

Are you curious why more Sponsors choose digital data collection methods over the traditional pen and paper? Read this recent white paper to discover the...

GLP Tissue Cross Reactivity Testing

GLP Tissue Cross Reactivity Testing

Precision for Medicine | 11-Oct-2021 | Product Brochure

Precision for Medicine's unique combination of research services and tissue procurement capabilities form the pillars of our GLP Tissue Cross Reactivity...

Related suppliers

Follow us


View more